Month: March 2026
78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes Excerpt from the Press Release: SAN DIEGO, March 26, 2026 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its…
Excerpt from the Press Release: SAN DIEGO, March 18, 2026 /PRNewswire/ — Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, today announced that the first patient has been dosed in the dose expansion phase of its clinical trial evaluating BTX-9341, a potent and…
Milestone marks first clinical evaluation of a targeted cell therapy designed to preserve natural insulin production POLARIS trial enrolling at 10 specialized clinic sites across the U.S. GentiBio on track to present key data in latter part of 2026 and 1H 2027 Excerpt from the Press Release: CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ — GentiBio, Inc.,…
First-in-human study underway evaluating anti-CD36 monoclonal antibody designed to restore metabolic fitness in exhausted T cells, reduce immunosuppressive cells, and enhance antitumor immunity Excerpt from the Press Release: DOVER, Del. & EPALINGES, Switzerland–(BUSINESS WIRE)–Pilatus Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced the first patient…
Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from the OPUS-1 Pivotal Noninferiority Trial Expected in the Fourth Quarter of 2026 At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity and…
The data, generated from a study designed to optimize ongoing test refinement, will be presented at the AACR Annual Meeting in April Excerpt from the Press Release: BRISBANE, Calif., March 18, 2026 /PRNewswire/ — Freenome, an early cancer detection company developing blood-based screening tests, today announced initial development data for its investigational lung cancer screening…
– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of –1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provided strong efficacy data in new analyses, including reduction in nasal congestion score (NCS) by -0.96 (p < 0.0001) – Excerpt from the Press Release:…
Excerpt from the Press Release: WALTHAM, Mass. and BOULDER, Colo., Feb. 28, 2026 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced additional clinical results from the pivotal SUMMIT trial with bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the American Academy…
Excerpt from the Press Release: BOSTON, Feb. 27, 2026 /PRNewswire/ — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced results from the first head-to-head study comparing urinary bladder radioactivity between two prostate-specific membrane antigen (PSMA)-targeted PET radiopharmaceuticals. This prospective, multicenter,…
Excerpt from the Press Release: MALVERN, Pa., March 02, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that enrollment is now complete for the OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP). As a one-year clinical trial,…